GT MedTech’s Innovative GammaTile Therapy Is Shown to Slow Brain Tumor Progression, Designed to Improve Patient and Caregiver Quality of Life HonorHealth Scottsdale Osborn Medical Center is First Hospital in State to Offer New Targeted Therapy for Recurrent Brain Tumors
SCOTTSDALE, Ariz. & TEMPE, Ariz.–(BUSINESS WIRE)–HonorHealth Scottsdale Osborn Medical Center is the first hospital in Arizona to begin offering GammaTile Therapy™, a new approach to treating recurrent brain tumors. GammaTile Therapy is an FDA-cleared, surgically targeted radiation therapy (STaRT) that is designed to delay tumor regrowth for patients with all types of recurrent brain tumors. The first patient was treated by John Wanebo, M.D., a neurosurgeon and an independent member of the HonorHealth medical staff.
“The first patient I was able to treat with GammaTile Therapy had a very large, aggressive meningioma that has recurred several times,” Dr. Wanebo said. “I am pleased to be able to offer this patient GammaTile Therapy – a treatment proven to delay brain tumor recurrence and improve quality of life. This therapy was developed with patients like this in mind, and I am hopeful that it will make a meaningful difference.”